Hepatitis C virus (HCV) infection is a known leading cause of liver-related morbidity and mortality, and effective antiviral treatments can result in a sustained virologic response (SVR), the surrogate marker for a cure. Direct-acting antiviral (DAA) is a newly developed class of HCV medicines. The new DAAs have become the new standard of care in many Western countries because of their value to patients and healthcare systems despite prices. The progress of HCV treatment shifting from interferon-containing regimens to interferon-free DAA regimens in Asia is also emerging. It is important to be able to evaluate the cost-effectiveness of new DAAs in Asian countries given different resource levels. This symposium will address the key drivers affecting treatment choice and cost-effectiveness of new DAAs in Asia, and summarize the health technology assessment (HTA) system and health economic evidence of HCV DAA treatments in Japan.